ATYR Stock — aTyr Pharma Inc.: Cash, EV, Pipeline

Share price

$0.36

Market cap

$35.6M

Cash

$57.4M

Enterprise value

-$21.8M

Balance sheet

Cash	$57.4M
Debt	$0.0M
Net cash	$57.4M
Enterprise value	-$21.8M
Basic shares	98.1M shares
Fully diluted shares	112.1M shares
Fully diluted market cap	$40.3M
Cash per share	$0.59

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading ATYR daily closes…

Loading price history…

Pipeline assets

Efzofitimod

Phase 3 · Active Modality: biologic (IV)

Target NRP2 (neuropilin-2)

Partnerships n/a (Kyorin Japan collaboration terminated effective Jul 30, 2026; Japan ILD rights reverted, company holds global rights)

Indications

Pulmonary sarcoidosis (Phase 3)
SSc-ILD (systemic sclerosis-associated ILD) (Phase 2)
Interstitial lung disease (Japan) (Phase 3)

Catalysts

— Q1 2027

Status note EFZO-FIT Phase 3 did not meet its primary endpoint (announced Sep 2025). After an FDA Type C meeting Apr 2026, the company plans a new Phase 3 with revised endpoints; protocol submitted Jun 2026. Study funding not yet secured; 60% workforce reduction Aug 2026.

ATYR0101

Preclinical · Active Modality: fusion protein (DARS domain + human Fc)

Target LTBP-1

Indications

Fibrotic diseases (pulmonary fibrosis, SSc, liver, kidney) (Preclinical)

Status note IND-enabling activities initiated; targets LTBP-1 in ECM; potential applications across pulmonary fibrosis, SSc, liver fibrosis and kidney fibrosis.

Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	efzofitimod 450 mg
Lead indication	Interstitial Lung Disease
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05892614	Phase 2	Recruiting	Sponsor	ATYR	—	Interstitial Lung Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for aTyr Pharma, Inc. on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	50,685	no change	0.00%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

ATYR — aTyr Pharma Inc.